Last Posted: May 20, 2019
- Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review.
Wright Stuart J et al. PharmacoEconomics 2019 May - The costliest drug on the planet will treat infants with rare disease. The market fight focused on cost and safety is just getting started.
C Rowland, NY Times, May 15, 2019 - Cost-effectiveness of newborn screening for severe combined immunodeficiency.
Van der Ploeg Catharina P B et al. European journal of pediatrics 2019 May 178(5) 721-729 - Repurposing large health insurance claims data to estimate genetic and environmental contributions in 560 phenotypes.
Lakhani Chirag M et al. Nature genetics 2019 51(2) 327-334 - An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities.
Thiboonboon Kittiphong et al. PloS one 2018 13(6) e0199318 - Building Linked Big Data for Stroke in Korea: Linkage of Stroke Registry and National Health Insurance Claims Data.
Kim Tae Jung et al. Journal of Korean medical science 2018 Dec 33(53) e343 - Economic evaluation of genomic sequencing in the paediatric population: a critical review.
Alam Khurshid et al. European journal of human genetics : EJHG 2018 26(9) 1241-1247 - The Uniformed Services University's Surgical Critical Care Initiative (SC2i): Bringing Precision Medicine to the Critically Ill.
Belard Arnaud et al. Military medicine 2018 183(suppl_1) 487-495 - Bayesian Networks for Risk Prediction Using Real-World Data: A Tool for Precision Medicine.
Arora Paul et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Apr 22(4) 439-445 - A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine.
Fahr Patrick et al. Applied health economics and health policy 2019 Apr
.png)
No hay comentarios:
Publicar un comentario